Skip to main content

Psilocybin has been used as a tool for self-growth and self- actualisation by allowing people to explore their full potential and to overcome limiting and negative patterns in their lives. Famous psychotherapists such as Carl Jung, Carl Rogers and Abraham Maslow talked of the importance of self actualisation, or integration.

Psychedelics play an important role in self-actualization by acting as a powerful tool in overcoming our default mode of thinking, which often provides limiting, discouraging, or misguided thoughts and beliefs. The experience of an altered state of mind and perspective can often act as a wake-up call, and helps people to break patterns that have been holding them back.

A study by Griffiths et al in the Journal of Psychopharmalogy July 2008 showed that  at the 14-month follow-up, 58% and 67%, respectively, of volunteers rated the psilocybin-occasioned experience as being among the five most personally meaningful and among the five most spiritually significant experiences of their lives; 64% indicated the experience increased well-being or life satisfaction; 58% met criteria for having had a “complete” mystical experience.

Attributions to the psilocybin experience also included positive changes in attitudes, mood, altruism, and other behaviours.






80% Remission Rate

High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.

At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety.

Johns Hopkins Study, Journal of Psychopharmacology  (Griffiths, et al, 2016)

Long-term Relief

The study showed that one-time treatment with the hallucinogenic drug psilocybin quickly brought relief from distress that then lasted for more than 6 months in 80 percent of the 29 study subjects monitored, based on clinical evaluation scores for anxiety and depression.

One of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study’s extended monitoring period—specifically, eight months for those who took psilocybin first.

NYU Study, Journal of Psychopharmacology (Ross, et al, 2016)

[siteorigin_widget class=”QT_Call_To_Action”][/siteorigin_widget]
[siteorigin_widget class=”QT_Call_To_Action”][/siteorigin_widget]